Assessment of Clinical Course, Prognostic Features, and Treatment Response of Patients with Chronic Lymphocytic Leukemia: A Single Center Experience

INTRODUCTION: We aimed to assess patients with chronic lymphocytic leukemia (CLL) with respect to their general clinical features, first-line treatments, survival time, and factors affecting treatment response.
METHODS: This study retrospectively enrolled 169 patients with available medical records of 188 patients who were under follow-up with CLL at Training and Research Hospital, Department of Hematology between 2009 and 2018.
RESULTS: Among 169 patients enrolled in the study, 90 were male and 79 were female; the study population had a median age of 65 (min 37-max 89) years. An analysis of Rai staging at the time of diagnosis revealed that fifty-seven (33.7%) patients had stage 0 disease; twenty-nine (17.2%) stage 1 disease; sixty-eight (40.2%) stage 2 disease; four (2.4%) patients stage 3 disease; and eleven (6.5%) patients stage IV disease. The mean duration of follow-up was 42.57 months; during that period, 134 (79.2%) patients received no therapy, and 35 (20.2%) patients received therapy. The first-line therapy was administered to 35 patients, of whom 16 (45.7%) received Rituximab-Fludarabin and Cyclophosphamide (R-FC); 5 (14.2%) Fludarabin and Cyclophosphamide (FC); 3 (8.5%) chlorambucil; 5 (14.2%) Rituximab-Chlorambucil; 2 (5.7%) the combination of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP); 2 (5.7%) Bendamustine; 1 (2.8%) the combination of cyclophosphamide, vincristine, and prednisone (CVP) and 1 (2.8%) Rituximab-CVP. The mean survival time of the untreated patients and treated patients were 99.4 months and 89.7 months, respectively. Thirty-eight (22.5%) patients died.
DISCUSSION AND CONCLUSION: The demographic features of our patients were similar to those reported in previous studies. An analysis of treatment-based survival time revealed that it was significantly longer in the untreated patients than the treated ones.

Kronik Lenfositik Lösemi Tanýlý Olgularýn Klinik Seyir, Prognostik Özellikler ve Tedavi Cevabý Yönünden Deðerlendirilmesi: Tek Merkez Deneyimi

GÝRÝÞ ve AMAÇ: Merkezimizde kronik lenfositik lösemi (KLL) tanýsý ile takipte olan hastalarýn genel klinik özellikleri, ilk sýra tedavileri, olgularýn yaþam süreleri ve bu yanýtlara etkili olabilecek faktörleri deðerlendirmeyi amaçladýk.
YÖNTEM ve GEREÇLER: Çalýþmada 2009-2018 yýllarý arasýnda Eðitim ve Araþtýrma Hastanesi Hematoloji Bölümünde KLL tanýsý ile izlenen 188 hastanýn dosyalarýna ulaþýlabilen 169’u retrospektif olarak deðerlendirildi.
BULGULAR: Çalýþmaya alýnan 169 hastadan 90’ý erkek, 79’u kadýn, median yaþ 65 (min37-max 89) idi. Taný anýnda Rai evrelemesine göre deðerlendirildiðinde evre 0 %33,7 (n: 57), evre I % 17,2 (n: 29), evre II % 40,2 (n: 68), evre III % 2,4 (n: 4), evre IV % 6,5 (n: 11) olduðu tespit edildi. Takip süresi ortalama 42,57 aydý ve bu süreçte 134 hasta (%79,2) hiç tedavi almazken, 35 hasta (%20,7) tedavi aldý. Ýlk sýra tedaviler incelendiðinde tedavi alan 35 hastanýn; 16’si (%45,7) Rituksimab-Fludurabin ve Siklofosfamid (R-FC), 5’i (%14,2) Fludarabin,Siklofosfamid (FC), 3’ü Klorambucil (% 8,5), 5’i Rituksimab-Klorambucil (%14,2), 2’si Rituksimab, Siklofosfamid, Doksorubisin, Vinkristine, ve Prednisone kombinasyonu (R-CHOP) (%5,7), 2’si Rituksimab-Bendamustin (%5,7), 1’i Siklofosfamid, Vinkristine, ve Prednisone kombinasyonu (CVP) ve 1’i CVP (%2,8) aldýðý görüldü. Tedavi almayan hastalarýn ortalama yaþam süresinin 99,4 ay, tedavi alan hastalarýn ortalama yaþam süresinin 89,7 ay olduðu tespit edilmiþtir. Hastalarýn 38’in de (%22,5) mortalite izlendi.
TARTIÞMA ve SONUÇ: Hastalarýmýzýn demografik özelliklerinin diðer çalýþmalarla benzer olduðu görülmüþtür. Tedavi alma durumuna göre sað kalým süresi incelendiðinde yaþam sürelerinin tedavi almayan grupta, tedavi alan gruba göre önemli düzeyde yüksek olduðu tespit edilmiþtir.